Skip to content
DataLookout
Menu

Boehringer Ingelheim clinical trial pipeline

Get alerts when Boehringer Ingelheim's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

36 trials changed in the last 30 days: 0 stopped, 10 with notable changes, 26 with minor changes only.

  1. Notable: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Recruitment opened Boehringer IngelheimPhase 3 NCT07855900
  2. Notable: SYNCHRONIZE®-HERA · Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Recruitment opened Boehringer IngelheimPhase 3 NCT07850050
  3. Minor: Beamion LUNG-3 · Adjuvant Zongertinib vs Standard Treatment · Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations Trial sites expanded: 202 → 205 locations Boehringer IngelheimPhase 3 NCT07195695
  4. Minor: ELEVATE-LIVER · Survodutide Helps Improve Heart Structure and Function · Overweight or Obesity and Fatty Liver Disease Trial sites expanded: 45 → 55 locations Boehringer IngelheimPhase 3 NCT07850063
  5. Notable: How Well BI 3000202 is Tolerated by · Type 1 Interferonopathies Primary completion pushed from Dec 6, 2026 to Dec 10, 2029 Boehringer IngelheimPhase 1 NCT06878365
  6. Minor: People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Primary and study completion dates pushed to Apr 9, 2027 Boehringer IngelheimPhase 1 NCT07407348
  7. Minor: Find Out if BI 764198 Helps Adults and · a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) Trial sites reduced: 316 → 309 locations Boehringer IngelheimPhase 3 NCT07220083
  8. Minor: Survodutide Helps · Type 2 Diabetes Control Their Blood Sugar Trial sites expanded: 101 → 121 locations Boehringer IngelheimPhase 3 NCT07754461
  9. Minor: BI 3810477 Helps · Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment Trial sites expanded: 37 → 42 locations Boehringer IngelheimPhase 2 NCT07926321
  10. Notable: Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood Enrollment reduced: 16 → 10 participants Boehringer IngelheimPhase 1 NCT07774325
  11. Notable: DAREON®-36 · Obrixtamig in Combination With ZL-1310 · Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Recruitment opened Boehringer IngelheimPhase 1/2 NCT07707895
  12. Notable: How Well Different Doses of BI 3821001 Are Tolerated by Healthy People Recruitment opened Boehringer IngelheimPhase 1 NCT07908004
  13. Minor: VERDANT · BI 771716 Helps · an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy Trial completed Boehringer IngelheimPhase 2 NCT06722157
  14. Minor: How BI 3000202 is Taken up in the Blood · and Without Liver Problems Trial completed Boehringer IngelheimPhase 1 NCT07486102
  15. Minor: Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States Primary and study completion pushed from Oct 30, 2026 to Jan 29, 2027 Boehringer IngelheimNot specified NCT07342309
  16. Minor: AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps · Bronchiectasis Trial sites reduced: 478 → 474 locations Boehringer IngelheimPhase 3 NCT06872892
  17. Minor: LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps · a Liver Disease Called NASH/MASH Who Have Cirrhosis Trial sites expanded: 446 → 449 locations Boehringer IngelheimPhase 3 NCT06632457
  18. Minor: People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) Trial sites expanded: 383 → 394 locations Boehringer IngelheimPhase 3 NCT07915219
  19. Minor: Survodutide Improves How the Body Uses Energy and Breaks Down Fat · Obesity Study completion moved earlier from Jan 10, 2027 to Dec 1, 2026 Boehringer IngelheimPhase 1 NCT06745284
  20. Minor: Healthy People to Measure How Different Doses of Verducatib Affect the Heart Enrollment closed, study ongoing Boehringer IngelheimPhase 1 NCT07760246
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-16 NCT07940244 A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations… Phase 1 Not Yet Recruiting
2026-11-10 NCT07929051 A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer… Phase 3 Not Yet Recruiting
2026-11-09 NCT07926308 Real-world Outcome of Zongertinib in Japan (J-HERZ) Not Yet Recruiting
2026-11-09 NCT07926321 A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When… Phase 2 Not Yet Recruiting
2026-11-09 NCT07926334 A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients… Phase 1 Not Yet Recruiting
2026-11-04 NCT07915219 A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With… Phase 3 Not Yet Recruiting
2026-10-30 NCT07907991 The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic… Phase 3 Not Yet Recruiting
2026-10-30 NCT07908004 A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People Phase 1 Recruiting

Active trials by phase

Phase 1
41
Phase 1/2
5
Phase 2
15
Phase 3
28
Not charted: 10 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 28

Get alerts when Boehringer Ingelheim's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free